|Enzon Pharmaceuticals Inc.|
20 Commerce Drive
United States - Map
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohns disease. The company was founded in 1981 and is based in Cranford, New Jersey.
|Enzon Pharmaceuticals Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 6; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Richard L. Feinstein CPA,
Chief Financial Officer and VP of Fin.
|Mr. Andrew Rackear J.D.,
Chief Exec. Officer and Sec.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|